Is NKTR a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Rezpegaldesleukin in atopic dermatitis, with q1 2026 revenue at ~$10.9M. The bear case rests on nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. Analysts covering it are spread from $80.00 to $192.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $80.00, +17.6% from the $68.00 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Rezpegaldesleukin in atopic dermatitis. The lead program targets a large, competitive dermatology market. The most optimistic analyst target on NKTR is $192.00, +182.4% from the $68.00 price. That figure is only reachable if this thesis works close to its best case.

Nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. Rezpegaldesleukin's pivotal outcomes are binary and years away (initial Phase 3 readouts guided around 2028), and clinical or regulatory setbacks could sharply affect the shares. The atopic dermatitis and alopecia areata markets are crowded with established biologics such as Dupixent and JAK inhibitors, so commercial success is not assured even with a positive trial. Additional capital raises could dilute existing holders, and the stock has historically been volatile around data and trial news. The most pessimistic published target is $80.00, +17.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Nektar Therapeutics is a San Francisco based, Nasdaq-listed clinical-stage biopharmaceutical company whose pipeline is anchored by rezpegaldesleukin (rezpeg), a first-in-class biol

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Rezpegaldesleukin in atopic dermatitis) stalling in the reported numbers rather than in the narrative, the risk above (nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Nektar is a clinical-stage biopharmaceutical company developing rezpegaldesleukin, a first-in-class biologic that stimulates regulatory T cells to help restore immune balance. It is being studied in immune and inflammatory conditions including atopic dermatitis, alopecia areata, and type 1 diabetes.

No. As a clinical-stage company, Nektar has no approved product revenue and runs operating losses while it funds trials. In Q1 2026 it reported ~$10.9M of revenue and a net loss of ~$44.9M. Low, volatile revenue is normal for this category rather than a red flag.

Rezpegaldesleukin (rezpeg) is Nektar's lead drug candidate, a regulatory T cell stimulator designed to expand Tregs and dampen harmful immune activity. Nektar regained full rights to it from Eli Lilly and is advancing it toward Phase 3 in atopic dermatitis and alopecia areata.